U.S. markets closed

Alpine Immune Sciences, Inc. (ALPN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
64.37-0.03 (-0.05%)
At close: 04:00PM EDT
64.32 -0.05 (-0.08%)
After hours: 07:17PM EDT

Alpine Immune Sciences, Inc.

188 East Blaine Street
Suite 200
Seattle, WA 98102
United States
206 788 4545

Full Time Employees142

Key Executives

NameTitlePayExercisedYear Born
Dr. Mitchell H. Gold M.D.Executive Chairman & CEO778.2kN/A1968
Dr. Stanford Peng M.D., Ph.D.President and Head of Research & Development751.2kN/A1971
Mr. Paul RickeySenior VP, CFO, Treasurer & Secretary577.1kN/A1979
Ms. M. Christina YiChief Technology OfficerN/AN/A1977
Temre JohnsonHead of IR & Corporate CommunicationsN/AN/AN/A
Dr. Remy Durand Ph.D.Chief Business OfficerN/AN/A1985
Dr. Wolfgang Dummer M.D., Ph.D.Chief Medical OfficerN/AN/A1966
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Corporate Governance

Alpine Immune Sciences, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 7; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.